---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028472"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:07:43.399139+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M

## Summary
- ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.
- 2024 ARCALYST revenue guidance $360-380M, ~59% YoY growth at midpoint.
- Q4 net income $25.2M vs $4.5M YoY; cash $206.4M, no debt, funds operations into at least 2027.
- Abiprubart Phase 2 Cohort 4 data and new development indication expected April 2024.

## SEC filing metadata
- accession: 0001104659-24-028472
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/tm247423d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028472
- JSON: https://secwatch.observer/filing/0001104659-24-028472.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028472.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported fourth quarter and full-year 2023 results: revenue $71.2 million and $233.2 million.
  - Period: fourth quarter and full-year 2023
  - Revenue: $71.2 million and $233.2 million
  - Result: reported results
  source text: ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported financial results for the fiscal year ended December 31, 2023.
  - Period: the fiscal year ended December 31, 2023
  - Result: reported results
  source text: On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.